Letter to Editor

May cyproheptadine be a treatment choice for prophylaxis of PFAPA syndrome?

Volume: 6 Number: 3 May 4, 2020
EN

May cyproheptadine be a treatment choice for prophylaxis of PFAPA syndrome?

Abstract

No abstract available.

Keywords

References

  1. 1. Feder HM, Salazar JC. A clinical review of 105 patients with PFAPA (a periodic fever syndrome). Acta Paediatr 2010;99:178-84.
  2. 2. Thomas KT, Feder HM Jr, Lawton AR, Edwards KM. Periodic fever syndrome in children. J Pediatr 2013;135:15.
  3. 3. Stojanov S, Hoffmann F, Kéry A, Renner ED, Hartl D, Lohse P, et al. Cytokine profile in PFAPA syndrome suggests continuous inflammation and reduced anti-inflammatory response. Eur Cytokine Netw 2006;17:90-7.
  4. 4. Müller T, Dürk T, Blumenthal B, Grimm M, Cicko S, Panther E, et al. 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One 2009;4:e6453.
  5. 5. Taniguchi K, Ono N, Sakai T, Ichiyama Y, Uemichi K. Response to cimetidine in a 1-year-old child with PFAPA syndrome. Turk J Pediatr 2016;58:687-9.

Details

Primary Language

English

Subjects

Immunology

Journal Section

Letter to Editor

Publication Date

May 4, 2020

Submission Date

December 28, 2019

Acceptance Date

January 31, 2020

Published in Issue

Year 2020 Volume: 6 Number: 3

APA
Ekici, A. (2020). May cyproheptadine be a treatment choice for prophylaxis of PFAPA syndrome? The European Research Journal, 6(3), 268-269. https://doi.org/10.18621/eurj.666806
AMA
1.Ekici A. May cyproheptadine be a treatment choice for prophylaxis of PFAPA syndrome? Eur Res J. 2020;6(3):268-269. doi:10.18621/eurj.666806
Chicago
Ekici, Arzu. 2020. “May Cyproheptadine Be a Treatment Choice for Prophylaxis of PFAPA Syndrome?”. The European Research Journal 6 (3): 268-69. https://doi.org/10.18621/eurj.666806.
EndNote
Ekici A (May 1, 2020) May cyproheptadine be a treatment choice for prophylaxis of PFAPA syndrome? The European Research Journal 6 3 268–269.
IEEE
[1]A. Ekici, “May cyproheptadine be a treatment choice for prophylaxis of PFAPA syndrome?”, Eur Res J, vol. 6, no. 3, pp. 268–269, May 2020, doi: 10.18621/eurj.666806.
ISNAD
Ekici, Arzu. “May Cyproheptadine Be a Treatment Choice for Prophylaxis of PFAPA Syndrome?”. The European Research Journal 6/3 (May 1, 2020): 268-269. https://doi.org/10.18621/eurj.666806.
JAMA
1.Ekici A. May cyproheptadine be a treatment choice for prophylaxis of PFAPA syndrome? Eur Res J. 2020;6:268–269.
MLA
Ekici, Arzu. “May Cyproheptadine Be a Treatment Choice for Prophylaxis of PFAPA Syndrome?”. The European Research Journal, vol. 6, no. 3, May 2020, pp. 268-9, doi:10.18621/eurj.666806.
Vancouver
1.Arzu Ekici. May cyproheptadine be a treatment choice for prophylaxis of PFAPA syndrome? Eur Res J. 2020 May 1;6(3):268-9. doi:10.18621/eurj.666806